Though regulatory victory by a competitor is seldom viewed with favor, Esperion Therapeutics Inc.'s harsh treatment on Wall Street in the aftermath of the FDA approval last week of Praluent (alirocumab) may have been overdone, and analysts continued to sift through the fallout Monday.